Glycopeptide Microarray

Glycopeptide Microarray

Antibodies against glycoproteins or glycopeptides generally recognize the peptide backbone as a portion of the binding epitope. Therefore, CD BioGlyco has developed a highly sensitive glycopeptide microarray platform to help our customers screen antibodies against specific glycopeptide antigens. We look forward to providing you with professional and rapid solutions in the research related to glycobiology microarray.


Abnormal post-translational variants of proteins may induce autoantibodies, and the change of O-linked glycosylation is one of the most significant cancer-related post-translational modifications. Short aberrant O-glycans on proteins may introduce new glycopeptide epitopes that can trigger autoantibodies. Therefore autoantibodies against cancer antigens are expected to serve as biomarkers for early cancer detection.

Currently, a new technology of glycopeptide microarray is being developed to screen for antibodies against different glycopeptide antigens and to detect glycopeptide-specific autoantibodies. Glycopeptide microarrays offer the advantages of parallelism, automation and rapidity. The parallel data detected has less error and higher precision. The emergence of this technology has played an important role in the advancement of many disciplines such as biology, genetics, clinical laboratory medicine and oncology.

Fig. 1 Microarray platform for detection of MUC1 O-glycopeptide–specific antibodies.Fig.1 Microarray platform for detection of MUC1 O-glycopeptide–specific antibodies. (Wandall, 2010)

Our Services

CD BioGlyco has developed glycopeptide microarray technology to help our customers map antibody epitopes and identify key residues for glycopeptide binding. Services we provide include but are not limited to:

  • We pre-synthesize glycopeptides of various structures and immobilize them on microarray slides. In several circumstances, glycopeptides are modified by specific enzymes (e.g. glycosyltransferases) in solution or in situ on the microarray slide. Constructed glycopeptide microarrays are incubated with interaction partners and then detected by fluorescence or other methods for binding events.
  • We use a chemoenzymatic approach to produce cancer-associated O-glycopeptide libraries in combination with a microarray platform for high-throughput detection of autoantibodies to the O-glycopeptidome. This technology allows sensitive detection of cancer-related autoantibodies to different O-glycopeptide epitopes.


  • Study on enzyme activities and substrate specificities
  • Mapping of antibody epitopes
  • Characterization of glycan-binding proteins
  • Discovery of clinical biomarkers

Advantages of Us

  • Advanced experimental platform and systematic data processing software
  • Strategies with high-throughput and high sensitivity
  • Professional scientist team
  • Customized services
  • Extensive experience in the field of glycobiology

With a large and well-equipped platform, CD BioGlyco provides high-quality glycopeptide microarray services to clients around the world, and we have comprehensive capabilities to meet your specific needs on glycopeptide microarray analysis. If you need our services, please contact us  for more details and technical support.


  1. Wandall, H.H.; et al. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Research. 2010, 70(4):1306-1313.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.